comparemela.com

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Card image cap

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Chad , Cambridge , Cambridgeshire , United Kingdom , Rose Weldon , Jeffrey Jones , Nasdaq , Twitter , Exchange Commission , Linkedin , Cullinan Oncology Inc , Oncology Announces First Patient Dosed , Novel Fusion Protein Uniquely Harnessing Both , Chief Medical Officer , Cullinan Oncology , Private Securities Litigation Reform Act , Annual Report ,

comparemela.com © 2020. All Rights Reserved.